Simultaneously targeting inflammatory response and parasite sequestration in brain to treat Experimental Cerebral Malaria

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Dende, Chaitanya ^a   Meena, Jairam ^b   Nagarajan, Perumal ^b   Panda, Amulya K ^b   Rangarajan, Pundi N ^a   Padmanaban, Govindarajan ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

^b NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEETHER; ARTEMISININ DERIVATIVE; CURCUMIN;

ANIMAL; BRAIN; COMBINATION DRUG THERAPY; DISEASE MODEL; DRUG EFFECTS; ENCEPHALITIS; ERYTHROCYTE; MALARIA, CEREBRAL; MOUSE; PARASITOLOGY; PLASMODIUM BERGHEI;

ANIMALS; ARTEMISININS; BRAIN; CURCUMIN; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENCEPHALITIS; ERYTHROCYTES; MALARIA, CEREBRAL; MICE; PLASMODIUM BERGHEI;

EID: 84938534977     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12671     Document Type: Article

References (46)

1. WHO World Malaria Report 2014 - World Health Organization, Geneva. Available at: www.who.int/malaria/publications/world-malaria-report-2014/en/ (2014). Accessed January 2nd, 2015.
2. Guidelines for the treatment of malaria. 2nd Edition. World Health Organization, Geneva. 35-Available at: http://whqlibdoc.who. int/publications/2010/9789241547925-eng.pdf?ua= 1 (2010). Accessed January 2nd, 2015.
3. Hunt, N. H. & Grau, G. E. Cytokines: accelerators and brakes in the pathogenesis of cerebral malaria. Trends Immunol. 24, 491-499 (2003).
4. Berendt, A. R., Turner, G. D. H. & Newbold, C. I. Cerebral malaria: the sequestration hypothesis. Parasitol. Today. 10, 412-414 (1994).
5. Taylor, T. E. et al. Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nature Med. 10, 143-145 (2004).
6. White, N. J., Turner, G. D. H., Medana, I. M., Dondorp, A. M. & Day, N. P. J. The murine cerebral malaria phenomenon. Trends Parasitol. 26, 11-15 (2010).
7. Craig, A. G. et al. The role of animal models for research on severe malaria. PLoS Pathog. 8, e1002401 (2012).
8. Baptista, F. G. et al. Accumulation of Plasmodium berghei-infected red blood cells in the brain is crucial for the development of cerebral malaria in mice. Infect. Immun. 78, 4033-4039 (2010).
9. Belnoue, E. et al. On the pathogenic role of brain sequestered α β CD8+ T cells in experimental cerebral malaria. J. Immunol. 169, 6369-6375 (2002).
10. Nitcheu, J. et al. Perforin-dependent brain-infiltrating cytotoxic CD8+ T lymphocytes mediate experimental cerebral malaria pathogenesis. J. Immunol. 170, 2221-2228 (2003).
11. Medana, I. M., Chaudhri, G., Chan-Ling, T. & Hunt, N. H. Central nervous system in cerebral malaria: "innocent bystander" or active participant in the induction of immunopathology? Immunol. Cell Biol. 79, 101-120 (2001).
12. Pino, P., Taoufiq, Z., Nitcheu, J., Vouldoukis, I. & Mazier, D. Blood brain barrier breakdown during cerebral malaria: suicide or murder? Thromb. Haemost. 94, 336-340 (2005).
13. Nie, C. Q. et al. IP-10 mediated T cell homing promotes cerebral inflammation over splenic immunity to malaria infection. PLoS Pathog. 5 e1000369 (2009).
14. Riley, E. M. et al. Neuropathogenesis of human and murine malaria. Trends Parasitol. 26, 277-278 (2010).
15. Zhao, H. et al. Olfactory plays a key role in spatiotemporal pathogenesis of cerebral malaria. Cell Host & Microbe 15, 551-563 (2014).
16. Renia, L. & Howland, S. W. Targeting the olfactory bulb during experimental cerebral malaria. Trends Parasitol. 30, 375-376 (2014).
17. Reddy, R. C., Vathsala, P. G., Keshamouni, V. G., Padmanaban, G. & Rangarajan, P. N. Curcumin for malaria therapy. Biochem. Biophys. Res. Comm. 326, 472-474 (2005).
18. Nandakumar, D. N., Nagaraj, V. A., Vathsala, P. G., Rangarajan, P. N. & Padmanaban, G. Curcumin-artemisinin combination therapy for malaria. Antimicrob. Agents Chemother. 50, 1859-1860 (2006).
19. Vathsala, P. G. et al. Curcumin-arteether combination therapy of Plasmodium berghei-infected mice prevents recrudescence through immunomodulation. PLoS One 7, e29422 (2012).
20. Akhtar, F., Rizvi, M. M. A. & Kar, S. Oral delivery of chitosan nanoparticles cures mice from Plasmodium yoelii infection. Biotechnol. Adv. 30, 310-320 (2011).
21. Waknine-Grinberg, J. H., McQuillan, J. A., Ginsberg, H. & Golenser, J. Modulation of cerebral malaria by fasudil and other immune-modifying compounds. Exp. Parasitol. 125, 141-146 (2010).
22. Yang, M. & Crawley, J. N. Simple behavioral assessment of mouse olfaction. Curr Protoc Neurosci. CHAPTER: Unit-8.24. doi:10.1002/0471142301.ns0824s48 (2009). Accessed December 22nd, 2013.
23. Armah, H. B. et al. Cerebrospinal fluid and serum biomarkers of cerebral malaria mortality in Ghanian children. Malaria J. 6, 147 (2007).
24. Lawrence, T. The nuclear factor NF-κ B pathway in inflammation. Cold Spring Harb Perspect Biol. 1, a001651. (2009).
25. Singh, S. & Aggarwal, B. B. Activation of transcription factor NF-κ B is suppressed by curcumin (diferuloylmethane). J. Biol. Chem. 270, 4995-5000 (1995).
26. Marin, Y. E. et al. Curcumin down regulates the constitutive activity of NF-κ B and induces apoptosis in novel mouse melanoma cells. Melanoma Res. 17, 274-283 (2007).
27. Buhrmann, C. et al. Curcumin modulates nuclear factor NF-κ B mediated inflammation in human tenocytes in vitro: role of the phosphatidylinositol 3-kinase/Akt pathway. J. Biol. Chem. 286, 28556-28566 (2011).
28. Vitatour, P., Merville, M. P., Bours, V. & Chariot, A. (2005). Phosphorylation of NF-κ B and I-κ B proteins: implications in cancer and inflammation. Trends Biochem. Sci. 30, 43-52 (2005).
29. Miu, J. et al. Chemokine gene expression during fatal murine cerebral malaria and protection due to CXCR3 deficiency. J. Immunol. 180, 1217-1230 (2008).
30. Campenella, G. S. V. et al. Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria. Proc. Natl. Acad. Sci. USA. 105, 4814-4819 (2008).
31. Belnoue, E. et al. Control of pathogenic CD8+ T cell migration to the brain by IFN-gamma during experimental cerebral malaria Parasite Immunol. 30, 544-553 (2008).
32. Prasad, S., Tyagi, A. K. & Aggarwal, B. B. Recent developments in delivery, absorption and metabolism of curcumin, the golden pigment from golden spice. Cancer Res. Treat. 46, 2-18 (2014).
33. He, X. et al. Vitamin D inhibits the occurrence of Experimental Cerebral Malaria in mice by suppressing the host inflammatory response. J. Immunol. 193, 1314-1323 (2014).
34. Waisberg, M., Vickers, B. K., Yager, S. B., Lin, C. K. & Pierce, S. K. Testing in mice the hypothesis that melanin is protective in malaria infections. PLoS One 7, e 29493 (2012).
35. Wilson, N. O. et al. Pharmacologic inhibition of CXCL10 in combination with anti-malarial therapy eliminates mortality associated with murine model of cerebral malaria. PLoS One 8, e 60898 (2014).
36. Souraud J. B. et al. Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model, Malaria J. 11, 13 (2012).
37. Jain V. et al. Plasma IP-10, apoptotic and angiogenic factors associated with fatal cerebral malaria in India. Malaria J. 7, 83 (2008).
38. Idro, R., Marsh, K., John, C. C. & Newton, C. R. J. Cerebral malaria; Mechanisms of brain injury and strategies for improved neuro-cognitive outcome. Pediatr. Res. 68, 267-274 (2010).
39. Padmanaban, G., Arun Nagaraj, V. & Rangarajan, P. N. Artemisinin-based combination with curcumin adds a new dimension to malaria therapy. Curr. Sci. 102, 704-711 (2012).
40. Mimche, P. N., Taramelli, D. & Vivas, L. The plant-based immunomodulator curcumin as a potential candidate for the development of an adjunctive therapy for cerebral malaria. Malaria J. 10, S10 (2011).
41. Jain, K., Sood, S. & Gowthaman, K. Modulation of cerebral malaria by curcumin as an adjunctive therapy. The Braz. J. Infect. Dis. 17, 579-591 (2013).
42. Chen, A. L. et al. Phase I clinical trial of curcumin, a chemo-preventive agent in patients with high risk or pre-malignant lesions. Anticancer Res. 21, 2895-2900 (2001).
43. May, L., Tourkina, E., Hoffman, S. R. & Dix, T. A. Detection and quantitation of curcumin in mouse lung cultures by matrixassisted laser desorption ionization time of flight mass spectrometry. Anal. Biochem. 337, 62-69 (2005).
44. Vareed, S. K. et al. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol. Biomarkers Prev. 17, 1411-1417 (2008).
45. Sehgal, N. et al. Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc. Natl. Acad. Sci. USA. 109, 3510-3515 (2012).
46. Claser, C. et al. CD8+ T Cells and IFN-γ mediate the time-dependent accumulation of infected red blood cells in deep organs during experimental cerebral malaria. PLoS One 6, e18720 (2011).